longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

WDM

600055

10.482.60% ( -0.28 )
Delay Closed: Sep 9, 15:00:00
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI

Current ValuationThe current P/E ratio is -19.87, below the reasonable range, cheaper than 90.66% of the time in the past 5 years, and the industry ranks 52/65, the industry Median 27.49.

-19.87xP/E
¥10.48Stock price
¥-0.53Earnings per share
-19.87xP/E
Stock price¥10.48Earnings per share¥-0.53

Historical Valuation

P/E ratioTypical rangeMedian
P/E ratio
73.67x
Typical range
53.06x–93.51x

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
Industry median 27.49x
013263952

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
Industry median 27.49x
0x30x60x90x120x150x
P/E ratio
Name/Symbol
300482SZWONDFO BIOTECH
-59.01x646.15%¥7.65B
600055SHWDM
-19.87x--¥7.37B
688277SHTinavi
-36.09x21.95%¥7.05B
300869SZCONTEC
-49.34x--¥4.47B
300318SZBohui Innovation
-47.45x--¥4.22B
688212SHAOHUA ENDOSCOPY
-121.43x170.37%¥4.06B
300246SZBIOLIGHT
-36.94x--¥3.89B
002932SZeDiagnosis
-71.09x--¥3.61B
688607SHCareRay
-118.92x--¥3.52B
301290SZCanopus
-82.12x--¥2.80B
300753SZAPON
-185.00x--¥2.69B
688576SHXishan Science&Technology
-332.37x--¥2.64B
300165SZSkyray Instrument
-12.70x--¥2.59B
300396SZDIRUI
-9.39x--¥1.97B
301515SZGangtong Medical
-153.75x--¥1.94B
688393SHLBP Medicine
-56.54x--¥1.91B

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.